Researchers treating patients with advanced/metastatic non–small cell lung cancer participated in the TROPION-Lung01 global phase III study. Of the participants, 299 received Dato-DXd and 305 received docetaxel.
In the overall trial population, Dato-DXd increased overall survival by 1.1 months. For patients with nonsquamous histology, survival increased by 2.3 months.
For patients with nonsquamous histology and actionable genomic alterations, Dato-DXd increased survival by 5.8 months. For patients with nonsquamous histology and no actionable genomic alterations, Dato-DXd increased survival by 1.3 months.
While the results showed a numerical benefit, they also showed Dato-DXd had no statistically significant effect on overall survival, the study authors wrote.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
